ERBB2 and breast carcinoma: Understanding ErbB2 interactomics and its regulation is a key factor to improve therapeutical approaches and overcome trastuzumab resistance, a clinical phenomenon that occurs in 66 to 88% of ErbB2-possitive metastatic breast cancers [14].